Live Broadcast to Explore a Newly Approved Treatment Option Available for Patients With Pretreated HR+/HER2-negative Metastatic Breast Cancer

In an upcoming live broadcast, watch your peers provide an overview of the unmet needs for patients with HR-positive, HER2-negative metastatic breast cancer who were previously treated with endocrine therapy. They will also discuss data on efficacy and safety of a newly approved treatment option in this setting, and will also touch on identification of patients with HR-positive, HER2-negative metastatic breast cancer who may be suitable for this regimen, as well as considerations regarding dosage, administration, and potential adverse event management.

To obtain clinical expert insights and learn about how this new therapy may impact your patients and your practice, watch the live broadcast on March 30, 2023 6:00 PM ET, 8:00 PM ET. To register for the event, visit https://studio.mjhassoc.com/reach/HER2neg-mBC.

This promotional program is sponsored by, and the speakers are presenting on behalf of, Gilead Sciences, Inc. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

© 2023 Gilead Sciences, Inc. All rights reserved. US-UNBP-1715 02/23